US 12,404,317 B2
T cell receptors recognizing MHC class II-restricted MAGE-A3
Paul F. Robbins, Chevy Chase, MD (US); Steven A. Rosenberg, Bethesda, MD (US); and Xin Yao, Rockville, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Sep. 28, 2022, as Appl. No. 17/936,006.
Application 16/812,845 is a division of application No. 15/848,344, filed on Dec. 20, 2017, granted, now 10,611,815, issued on Apr. 7, 2020.
Application 15/848,344 is a division of application No. 14/427,671, granted, now 9,879,065, issued on Jan. 30, 2018, previously published as PCT/US2013/059608, filed on Sep. 13, 2013.
Application 17/936,006 is a continuation of application No. 16/812,845, filed on Mar. 9, 2020, abandoned.
Claims priority of provisional application 61/701,056, filed on Sep. 14, 2012.
Prior Publication US 2023/0089465 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/725 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); C07K 14/73 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 38/1774 (2013.01); A61K 39/0005 (2013.01); C07K 14/70514 (2013.01); C07K 16/00 (2013.01); C07K 16/2809 (2013.01); G01N 33/57492 (2013.01); A61K 2039/585 (2013.01); C07K 2319/00 (2013.01); G01N 2333/47 (2013.01); G01N 2333/7051 (2013.01)] 20 Claims
 
1. A method of producing an engineered population of human cells, the method comprising:
introducing a recombinant expression vector to an isolated population of human cells, wherein the recombinant expression vector comprises a nucleotide sequence encoding a T-cell receptor (TCR) having antigenic specificity for MAGE-A3243-258 and MAGE-A6, wherein the TCR comprises the amino acid sequences of:
(a) SEQ ID NOs: 3, 4, 6, 7,
(i) SEQ ID NO: 29, wherein:
Xaa4 is Ser, Ala, Leu, Ile, Val, or Met;
Xaa5 is Ser, Ala, Leu, Ile, Val, or Met;
Xaa6 is Gly, Ala, Leu, Ile, Val, or Met; and
Xaa7 is Thr, Ala, Leu, Ile, Val, or Met; and
(ii) SEQ ID NO: 30, wherein:
Xaa4 is Arg, Ala, Leu, Ile, Val, or Met;
Xaa5 is Thr, Ala, Leu, Ile, Val, or Met;
Xaa6 is Gly, Ala, Leu, Ile, Val, or Met; and
Xaa7 is Pro, Ala, Leu, Ile, Val, or Met; or
(b) SEQ ID NOs: 3-8.